





ATC codes: **N04BA02**

Indication	Parkinson disease <span style="background-color: #0070C0; color: white; padding: 2px;">ICD11 code: 8A00.0Z</span>
INN	Levodopa + carbidopa
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Solid: 100 mg + 10 mg tablet ; 250 mg + 25 mg tablet ; 100 mg + 25 mg tablet
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 1982 ( <a href="#">TRS 685</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2013 ( <a href="#">TRS 985</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	levodopa + benserazide (ATC codes: N04BA02)
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Levodopa + carbidopa</a> 
DrugBank	<a href="#">Levodopa</a>  <a href="#">Carbidopa</a> 

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended benserazide be specified as a therapeutic alternative for the carbidopa component under the square box listing for levodopa + carbidopa on the EML.

